Physician profile
Ronald L Johnson
NPI 1467487686
$1,512.13
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $843 · 2021: $13.38 · 2022: $13.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $215.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $173.27 | 2019-2020 | |
| Pfizer INC. | $161.87 | 2019-2020 | |
| Lilly USA, LLC | $101.52 | 2019-2020 | |
| Amarin Pharma, INC. | $91.59 | 2020 | |
| Merck Sharp & Dohme LLC | $48.34 | 2019 | |
| Dexcom, INC. | $46.81 | 2020 | |
| Insulet Corporation | $33.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $33.36 | 2019 | |
| Ibsa Pharma INC. | $33.35 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $27.85 | 2020 | |
| Abbvie INC. | $26.88 | 2021-2022 | |
| Medtronic Minimed, INC. | $25.53 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.39 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.23 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.51 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.